Sonnet Biotherapeutics Shares Owned By Institutions vs. Total Debt

SONN Stock  USD 2.63  0.14  5.05%   
Based on Sonnet Biotherapeutics' profitability indicators, Sonnet Biotherapeutics Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Sonnet Biotherapeutics' ability to earn profits and add value for shareholders. As of the 29th of November 2024, Price To Sales Ratio is likely to drop to 1.12. In addition to that, Days Sales Outstanding is likely to drop to 3.67. At this time, Sonnet Biotherapeutics' Interest Income is very stable compared to the past year. As of the 29th of November 2024, Change To Netincome is likely to grow to about 10.4 M, while Accumulated Other Comprehensive Income is likely to drop (212.2 K).
For Sonnet Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sonnet Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sonnet Biotherapeutics Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sonnet Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sonnet Biotherapeutics Holdings over time as well as its relative position and ranking within its peers.
  

Sonnet Biotherapeutics' Revenue Breakdown by Earning Segment

Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Revenue Per Share
0.019
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.97)
Return On Equity
(2.65)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sonnet Biotherapeutics Total Debt vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sonnet Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Sonnet Biotherapeutics value to that of its competitors to determine the firm's financial worth.
Sonnet Biotherapeutics Holdings is rated below average in shares owned by institutions category among its peers. It is rated below average in total debt category among its peers making up about  334,280  of Total Debt per Shares Owned By Institutions. As of the 29th of November 2024, Total Debt To Capitalization is likely to grow to 0.70. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonnet Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Sonnet Biotherapeutics' Earnings Breakdown by Geography

Sonnet Total Debt vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Sonnet Biotherapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
0.61 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Sonnet Biotherapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
203.91 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Sonnet Total Debt vs Competition

Sonnet Biotherapeutics Holdings is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 535.45 Million. Sonnet Biotherapeutics adds roughly 203,911 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Workforce  Capitalization  Revenue  Valuation

Sonnet Biotherapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sonnet Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sonnet Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sonnet Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Sonnet Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-202.1 K-212.2 K
Operating Income-4.7 M-4.9 M
Income Before Tax-4.9 M-5.1 M
Total Other Income Expense Net-162.9 K-171 K
Net Loss-4.9 M-5.1 M
Net Loss-17.4 M-18.3 M
Non Operating Income Net Other-556.1 K-528.3 K
Net Loss-16.1 M-16.9 M
Income Tax Expense162.9 K154.7 K
Interest Income606.2 K955 K
Net Interest Income-187.3 K-177.9 K
Change To Netincome9.9 M10.4 M
Net Loss-15.6 K-16.4 K
Income Quality 0.16  0.15 
Net Income Per E B T 0.98  1.24 

Sonnet Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sonnet Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sonnet Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sonnet Biotherapeutics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Sonnet Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Use Investing Themes to Complement your Sonnet Biotherapeutics position

In addition to having Sonnet Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Growth Thematic Idea Now

Tech Growth
Tech Growth Theme
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out World Market Map.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project Sonnet Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sonnet Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sonnet Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Sonnet Biotherapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sonnet Biotherapeutics investors may work on each financial statement separately, they are all related. The changes in Sonnet Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sonnet Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.